EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY 4.0

Optimal adjuvant strategy in intermediate-risk cervical cancer: a systematic review and meta-analysis

Akira Yokoi, Hiroko Machida, Mika Okazawa-Sakai, Koji Nishino, Hanae Sekine, Mizue Itoi, Takumi Mitamura, Fumiaki Isohashi, Keisuke Tsuchida, Haruya Saji, Satoe Fujiwara, Noriko Ii und 14 weitere

International Journal of Clinical Oncology · 2026-06 · 31 (6) · 1084-1095

DOI: 10.1007/s10147-026-03028-9 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift International Journal of Clinical Oncology, online erschienen am 21.04.2026. Verfasst von Akira Yokoi und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Nagoya University, Aichi, Japan. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Chemoradiotherapy, Adjuvant. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Tokai University, Isehara Campus.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To evaluate the efficacy and safety of adjuvant treatment strategies following radical hysterectomy for intermediate-risk, early-stage cervical cancer using a reconstructed HR Hazard ratio (HR) meta-analysis.

Methods

A systematic review and meta-analysis was conducted by the Japan Society of Gynecologic Oncology Cervical Cancer Committee. PubMed/MEDLINE, Cochrane, and Ichushi were searched on July 29, 2025, using “cervical cancer,” “intermediate-risk,” and “adjuvant therapy.” Studies comparing adjuvant radiotherapy alone (RT) with no further treatment (NFT), concurrent chemoradiotherapy (CCRT), or systemic chemotherapy (CT) after conventional radical hysterectomy were independently reviewed by two reviewers. Primary outcomes were survival and grade ≥ 3 treatment-related toxicities.

Results

Of 402 screened articles, 24 studies comprising 9278 patients were included: RT ( n = 4167), NFT ( n = 2057), CCRT ( n = 2118), and CT ( n = 936). The majority of studies enrolled patients with ≥ 2 Sedlis risk factors (median 84.2%, interquartile range 44.7–100%). Compared with NFT, RT significantly improved recurrence-free survival (HR 0.61, P < 0.01) but did not confer a significant overall survival benefit (HR 0.77, P = 0.09). RT also reduced recurrence in patients with a single risk factor (HR 0.55, P < 0.01). RT showed no survival disadvantage compared with CCRT (recurrence-free survival: HR 1.26; overall survival: HR 1.07), and survival outcomes were comparable between RT and CT (recurrence-free survival: HR 0.86; overall survival: HR 1.16) (all P > 0.05). Grade ≥ 3 toxicities were significantly lower with RT than with CCRT (odds ratio 0.25; P < 0.001).

Conclusion

Adjuvant RT represents an effective and well-tolerated postoperative strategy for intermediate-risk, early-stage cervical cancer. Adjuvant CT may represent a potential alternative option.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Uterine Cervical NeoplasmsChemoradiotherapy, AdjuvantFemaleHumansHysterectomyRadiotherapy, AdjuvantChemotherapy, AdjuvantRisk FactorsNeoplasm Recurrence, Local

Stichwörter der Autor:innen

Cervical cancerComplicationsIntermediate-riskSurvivalSystematic review

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Nagoya University, Aichi, Japan.
  • Department of Obstetrics and Gynecology, Tokai University School of Medicine, Shimokasuya, Isehara, Kanagawa, Japan. hiroko.machida@tokai.ac.jp.
  • Department of Gynecologic Oncology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Ehime, Japan.
  • Department of Gynecologic Oncology, Niigata Cancer Center Hospital, Niigata, Japan.
  • Department of Obstetrics and Gynecology, Faculty of Medicine, Juntendo, University, Tokyo, Japan.
  • Department of Gynecologic Oncology, Chiba Cancer Center, Chiba, Japan.

Förderung

  • Tokai University, Isehara Campus

Zitieren

APA

Yokoi, A., Machida, H., Okazawa-Sakai, M., Nishino, K., Sekine, H., Itoi, M., Mitamura, T., Isohashi, F., Tsuchida, K., Saji, H., Fujiwara, S., Ii, N., Watanabe, M., Nishikawa, T., Nakagawa, S., Kodama, M., Sato, S., Takehara, K., Morisada, T., …, & Okamoto, A. (2026). Optimal adjuvant strategy in intermediate-risk cervical cancer: a systematic review and meta-analysis. International Journal of Clinical Oncology, 31(6), 1084-1095. https://doi.org/10.1007/s10147-026-03028-9

Vancouver

Yokoi A, Machida H, Okazawa-Sakai M, Nishino K, Sekine H, Itoi M, et al. Optimal adjuvant strategy in intermediate-risk cervical cancer: a systematic review and meta-analysis. International Journal of Clinical Oncology. 2026;31(6):1084-1095. doi:10.1007/s10147-026-03028-9

BibTeX
@article{Yokoi2026,
  author = {Yokoi, Akira and Machida, Hiroko and Okazawa-Sakai, Mika and Nishino, Koji and Sekine, Hanae and Itoi, Mizue and Mitamura, Takumi and Isohashi, Fumiaki and Tsuchida, Keisuke and Saji, Haruya and Fujiwara, Satoe and Ii, Noriko and Watanabe, Miho and Nishikawa, Tadaaki and Nakagawa, Satoshi and Kodama, Michiko and Sato, Shinya and Takehara, Kazuhiro and Morisada, Tohru and Noda, Shin-Ei and Takekuma, Munetaka and Kajiyama, Hiroaki and Tokunaga, Hideki and Baba, Tsukasa and Kobayashi, Yoichi and Okamoto, Aikou},
  title = {Optimal adjuvant strategy in intermediate-risk cervical cancer: a systematic review and meta-analysis},
  journal = {International Journal of Clinical Oncology},
  year = {2026},
  volume = {31},
  number = {6},
  pages = {1084--1095},
  doi = {10.1007/s10147-026-03028-9}
}
Kostenlos starten →